Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of APDN’s Linea DNA™ for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML

May 13, 2024

Read More

APDN Announces Second Quarter Fiscal Year 2024 Financial Results

May 10, 2024

Read More

APDN Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 10, 2024

Read More

APDN Awarded Contract by HDT Bio For Rapid Vaccine Development Program

April 25, 2024

Read More

Applied DNA Announces 1-For-20 Reverse Stock Split

April 22, 2024

Read More

Applied DNA, Alphazyme Agreement for Scale-Up Linea™ RNAP

March 18, 2024

Read More

APDN to Showcase Linea™ DNA, Linea™ IVT Platforms at World Vaccine Congress

March 14, 2024

Read More

APDN Announces First Quarter Fiscal Year 2024 Financial Results

February 8, 2024

Read More

APDN to Report FQ1’2024 Financial Results on Thursday, February 8, 2024

February 5, 2024

Read More